Pharmaceutical Preparations · DE · CIK 1570562
Evolus, Inc. provides breakthrough injectable neurotoxins and hyaluronic acid gels for the cash-pay aesthetic market
Comparable business profile · signals at a glance
In the 90 days to Mar 20, 2026: 2 sold $889K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 20, 2026 | Moatazedi DavidSee Remarks | Sell | 13,669 | $4.75 | $65K |
| Mar 20, 2026 | Avelar RuiSee Remarks | Sell | 3,119 | $4.75 | $15K |
| Mar 17, 2026 | Moatazedi DavidSee Remarks | Sell | 116,720 | $4.89 | $571K |
| Mar 17, 2026 | Avelar RuiSee Remarks | Sell | 29,996 | $4.89 | $147K |
| Dec 22, 2025 | Moatazedi DavidSee Remarks | Sell | 10,539 | $7.15 | $75K |
| Dec 22, 2025 | Avelar RuiSee Remarks | Sell | 2,261 | $7.15 | $16K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.